Seres Therapeutics shares are trading higher after the company announced the first patient has been enrolled in the SER-155 Phase 1b study.

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.